| Name | Title | Contact Details |
|---|
Most patients who are prescribed blockbuster therapies today don`t respond to the treatment, costing the health care industry billions in wasted drugs while patients continue to suffer. Scipher`s platform identifies which drug will work based on the patient`s fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A simple test predicts which drug he/she will respond to, ensuring that most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.
Biomea Fusion, Inc. was formed in 2017 by a small group of biotech executives. We are dedicated to developing innovative medicines for patients. It is our goal to design and clinically develop patient friendly therapies with higher efficacy than the current standard of care.
Sapient enables discovery of circulating biomarkers at unprecedented speed & scale, providing a deeper understanding of human biology to align patients & drug therapies.
Eyetech Pharmaceuticals, Inc. is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are committed to helping people with severe, chronic cardiovascular diseases realize the promise of patient-specific, expanded multicellular therapy.